AMLX (Amylyx Pharmaceuticals) EPS without NRI: $-1.50 (TTM As of Mar. 2026)


AMLX Amylyx Pharmaceuticals Inc AMLX
33 GF Score
Price $18.28
! 3 Warning Signs
View Full Analysis

What is Amylyx Pharmaceuticals EPS without NRI?

Amylyx Pharmaceuticals AMLX +1.81% 33 EPS without NRI is $-1.50 as of Mar. 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 787 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks better than 69.89% on this metric.

Amylyx Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.37. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.50.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 23.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Amylyx Pharmaceuticals's EPS without NRI or its related term are showing as below:

AMLX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -119.2   Med: -30.8   Max: 23.3
Current: 23.3

During the past 7 years, Amylyx Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 23.30% per year. The lowest was -119.20% per year. And the median was -30.80% per year.

AMLX's 3-Year EPS without NRI Growth Rate is ranked better than
69.89% of 787 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs AMLX: 23.30

Amylyx Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.37. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.50.

Amylyx Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2026 was $-0.37. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.50.


Amylyx Pharmaceuticals  (NAS:AMLX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Amylyx Pharmaceuticals EPS without NRI Related Terms


Amylyx Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for Amylyx Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amylyx Pharmaceuticals EPS without NRI Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial -1.59 -3.39 0.70 -3.56 -1.53

Amylyx Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.46 -0.37 -0.30 -0.37

AMLX vs ANIP, TRLV, PBH: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amylyx Pharmaceuticals PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Amylyx Pharmaceuticals's PE Ratio without NRI falls into.


AMLX
33GF Score
Amylyx Pharmaceuticals Inc AMLX
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amylyx Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-1.50 mean?
Amylyx Pharmaceuticals (AMLX) has a EPS without NRI of $-1.50 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Amylyx Pharmaceuticals and its competitors. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #237 out of 787 companies in the Drug Manufacturers industry, placing it in the top 30.1%.
Is Amylyx Pharmaceuticals' EPS without NRI too high?
Amylyx Pharmaceuticals' current EPS without NRI is $-1.50. Based on the distribution chart, Amylyx Pharmaceuticals ranks #237 out of 787 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' EPS without NRI compare to ANIP and TRLV?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #237 out of 787 companies for EPS without NRI. This puts Amylyx Pharmaceuticals in the upper half of its industry. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Amylyx Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current EPS without NRI is $-1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current EPS without NRI of $-1.50. The current EPS without NRI is $-1.50. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current EPS without NRI is $-1.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amylyx Pharmaceuticals Business Description

Address 55 Cambridge Parkway, Suite 6W, Cambridge, MA, USA, 02142
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score

Get the complete analysis for AMLX

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.28
Price